← FDA DRUG APPROVALS

FDA NDA · NDA020749

LAMISIL

Sponsor: KARO HLTHCARE

APPLICATION
NDA020749
TYPE
NDA
ORIGINAL APPROVAL
1997-10-17
LATEST ACTION
2003-03-27
ROUTE
TOPICAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

LAMISILDiscontinued
TERBINAFINE HYDROCHLORIDE 1% · SOLUTION · TOPICAL

Approval history

2003-03-27Labeling · Supplement 4 · standardLetterAP
2002-08-02Manufacturing (CMC) · Supplement 8 · standardAP
2002-01-22Manufacturing (CMC) · Supplement 7 · standardAP
2001-12-27Manufacturing (CMC) · Supplement 6 · standardAP
2001-04-30Manufacturing (CMC) · Supplement 5 · standardAP
1999-05-13Manufacturing (CMC) · Supplement 2 · standardAP
1997-10-17Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →